<DOC>
	<DOCNO>NCT00587847</DOCNO>
	<brief_summary>This study design test whether give campath ( also know alemtuzumab ) maintenance schedule prolong time patient require chemotherapy .</brief_summary>
	<brief_title>Campath Maintenance Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This open-label , single arm , proof-of-principle study Campath ( also know alemtuzumab ) maintenance therapy administer subcutaneously vary interval 1 year . Ongoing prophylactic anti-infectives provide . Patients assessed response every 2 month quality life every 3 month treatment . Patients achieve presumptive complete response receive treatment follow response . Non-responding patient , confirm progress disease follow minimum 8 dos discontinue treatment follow survival . Responding patient patient stable disease undergo confirmatory assessment 2 month follow end-of-treatment assessment . If remission occur , patient follow treatment documented disease progression .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Enrollment study open patient 18 year age confirm chronic lymphocytic leukemia , clinical response stable disease well previous treatment , Eastern Cooperative Oncology Group performance status 02 Treatment failure 3 prior regimen Active secondary malignancy Central nervous system involvement CLL History significant allergic reaction antibody therapy require discontinuation antibody therapy History HIV positivity Hepatitis C virus ( HCV ) positivity base upon core antigen test Active infection , require treatment antibiotic , antiviral , antifungal agent Pregnancy lactation Other severe , concurrent disease mental disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>leukemia</keyword>
</DOC>